Gerresheimer

Sustainability is a key pillar of our business strategy. For us thinking and acting sustainably means taking a long-term view of our impact as a company. Our success is largely due to the commitment of all our employees. Read our Non-Financial Report to learn more about our sustainability goals: https://lnkd.in/ePH_6h-i

Don't miss our presentation on this topic at Pharmapack Europe: The innovation journey: Developing EZ-fill Smart as the New Industry Standard for Ready-to-Use Vials Our spokesman Holger Krenz will inform you about the latest status of our development and answer your questions. Here you can find all information about our presence at Pharmapack:  https://lnkd.in/ebeQptkj #innovatingforabetterlife #vials #presentation #pharma #biotech #pharmaceuticalpackaging #packagingsolution

At the Pre-filled Syringes and Injectable Drug Devices Conference on January 15-16 in London Mithun Ratnakumar will discuss the role of connected devices and digital health in supporting patient adherence and symptom management. Are you considering whether your next drug delivery device should have connectivity? Hear from Mithun why we believe connectivity and digital health solutions can play a key role in the future of patient-centric healthcare. #innovatingforabetterlife #injectables #drugdevices #drugdelivery #pharma #biotech #healthcare

Meet us on Pharmapack 2025 in January 22-23, 2025!  Our team and the Bormioli Pharma Team welcomes you to our first common fair presentation. Visit our booth F55, browse our comprehensive product range or talk to our experts. Get insights on how we could support you with our best-in-class containment solutions and innovative drug delivery devices at Pharmapack in Paris. Click here to make an appointment and for all information about Pharmapack: https://lnkd.in/ebeQptkj #innovatingforabetterlife #pharmapack #pharma #biologics #drugdelivery #drugdevices

"The regulatory authority's decision underlines the market readiness of our on-body drug delivery device," said Dietmar Siemssen, CEO of Gerresheimer AG. "It also clearly demonstrates our expertise as an innovative solution provider for our customers, from product design to regulatory submission and large-scale manufacturing." The US Food and Drug Administration (FDA) granted @SQ Innovation Tentative Approval for Lasix ONYU for the home treatment of fluid overload in congestive heart failure. Lasix ONYU is a combination product consisting of a novel high-concentration formulation of the diuretic furosemide and the Gerresheimer on-body drug delivery device. Read our press release: https://lnkd.in/eFpwpdt2 #innovatingforabetterlife #fda #drugdeliverydevice #biologics #smallmolecules #largemolecules #pharma 

Join us at Pharmapack Europe in Paris and see how our experts can make your next drug delivery project a reality. Contact our colleagues to get your free ticket or arrange a meeting: Wolfgang Grunauer, Florian Reinhardt, Krisztian Hetey. #drugdeliverysystems #medicalproduct #productdevelopment #contractmanufacturing #industrialization #pharmapack #cleanroomproduction #assembly #highvolumeassembly #highvolumeproduction

Welcome to the Gerresheimer family! Yesterday our Gerresheimer Management Board met Bormioli Pharma for the first town hall meeting. The meeting kicked off with an emotional opening video titled "Two Stories – One Future," setting a collaborative and visionary tone for the event. Dietmar Siemssen extended a warm welcome to all Bormioli Pharma colleagues, underscoring the unity and joint mission of Bormioli Pharma and Gerresheimer. #innovatingforabetterlife #bormiolipharma #acquisition #pharma #biotech #healthcare #twostoriesonefuture

"Following the successful completion of the acquisition, we can now focus on the integration of Bormioli Pharma into the Gerresheimer Group," explains Dietmar Siemssen, our CEO. "We are convinced that our customers will benefit from the expansion of the product portfolio and new, integrated systems and solutions." We have successfully completed the acquisition of Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group announced in May 2024. With this acquisition, we strengthen our European footprint with additional production sites and underpin our market position as a leading full-service provider and global partner for the pharma and biotech industries. Link to our press release: https://lnkd.in/gnsCFr7M #innovatingforabetterlife #bormiolipharma #acquisition #pharma #biotech #healthcare #twostoriesonefuture

Patient-centric solution for home-administration of immunotherapy in oncology. Transferring therapy from the clinic to the home can pose challenges for patient useability and symptom management. By connecting our user-centric Gx SensAir® on-body device to Aptar Digital Health’s platform, pharmaceutical companies benefit from an integrated patient-centric solution. Visit our webpage to find out more and set up a meeting. Our experts would love to discuss how we can deliver streamlined customization of our solution to meet your needs. Book a video call & find out more about our solution https://lnkd.in/eRW9ubrx Our experts are: Sueyoung Yoon, Digital Solution Lead and Moritz Mond, Product Manager #innovatingforabetterlife #immunotherapy #oncology #drugdelivery #pharma #biotech #digitalhealth

Developing a large molecule formulation for subcutaneous home delivery? Need a reliable, user-centric, single-dose device that can deliver up to 3 mL? Look no further than our novel Gx Inbeneo® autoinjector platform that recently won a Red Dot award for Design Concept. The innovative pre-pressurized, cartridge-based system with dry needle, supports smooth, safe self-administration of biologics with no risk of clogging during storage. Read our new whitepaper to discover how our comprehensive testing proves that our innovative Gx Inbeneo® meets your needs in large molecule drug delivery. #innovatingforabetterlife #autoinjector #drugdelivery #drugdevice #pharma #biotech #healthcare